Pirtobrutinib

• A prospective, open-label, randomized, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R… Pending
  2024-513445-37-00 Phase III 4 countries University Of Cologne
• Study PACIFIC: Fixed duration treatment with combined pirtobrutinib and short course immuno-chemotherapy in fit patients with previously unt… Pending
  2025-521199-80-00 Phase II 1 country French Innovative Leukemia Organization
• PirtobrUtinib as frontline Therapy for elderly unfit/frail patient with MAntle cell lymphoma: a phase II study of the Fondazione Italiana Li… Pending
  2025-521666-10-01 Phase II 1 country Fondazione Italiana Linfomi Ets
• PIRTOBRUTINIB AND GLOFITAMAB IN MANTLE CELL LYMPHOMA Recruiting
  2024-512922-27-00 Phase II 5 countries Klinikum der Universitaet Muenchen AöR
• Clinical trial to evaluate the efficacy and safety of pirtobrutinib in combination with rituximab in patients with indolent clinical forms o… Recruiting
  2024-511983-97-00 Phase II 2 countries Fundacion Geltamo
• A Study to Investigate the Safety and Efficacy of Pirtobrutinib in Adults with Immune Thrombocytopenia Recruiting
  2024-518502-40-00 Phase I/II 6 countries Eli Lilly & Co.
• A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic … Recruiting
  2025-522860-34-00 Phase III 10 countries BeOne Medicines AG
• A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (… Recruiting
  2023-510294-34-00 Phase III 14 countries University Of Cologne
• A Phase 3 Study Comparing Pirtobrutinib to Ibrutinib in CLL/SLL Recruiting
  2023-507699-38-00 Phase III 9 countries Loxo Oncology Inc.
• This study is to evaluate the safety and tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin… Recruiting
  2023-505347-38-00 Phase I/II 7 countries AbbVie Deutschland GmbH & Co. KG
• A Phase 3 Study Comparing Pirtobrutinib (LOXO-305) to Bendamustine plus Rituximab in Untreated Patients with CLL/SLL Ended
  2024-511599-33-00 Phase III 10 countries Loxo Oncology Inc.
• A Phase 3 Trial of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treat… Ended
  2023-507698-16-00 Phase III 11 countries Loxo Oncology Inc.
• A Phase 3 Open Label, Randomized Study of LOXO 305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab … Ended
  2023-507697-40-00 Phase III 11 countries Loxo Oncology Inc.
• A clinical study to assess the effectiveness and safety of LOXO-305 compared to standard of care treatment chosen by the Investigator in pat… Ended
  2023-507695-52-00 Phase III 11 countries Loxo Oncology Inc.
• Safety and Efficacy Study of Epcoritamab in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome Ended
  2023-504828-25-00 Phase I/II 9 countries Genmab A/S
• An Early Phase Study with the Drug LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL… Ended
  2023-509270-37-00 Phase I (FiH) 3 countries Loxo Oncology Inc.

Showing 1–16 of 16 trials